Hypofractionated Radiotherapy
Hypofractionated Radiotherapy is a radiation therapy with 57 clinical trials. Currently 19 active trials ongoing. Historical success rate of 86.7%.
Success Metrics
Based on 13 completed trials
Phase Distribution
Phase Distribution
13
Early Stage
19
Mid Stage
7
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
76.5%
13 of 17 finished
23.5%
4 ended early
19
trials recruiting
57
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer ( EV-309 )
Hypofractionated Radiotherapy for Postoperative Intermediate-Risk Head and Neck Squamous Cell Carcinoma
Hypofractionated Radiation Therapy vs Standard Treatment in Breast Cancer.
Faecal Incontinence in Prostate Cancer Survivors Treated Whith Radiotherapy
BreastVAX: Radiation Boost to Enhance Immune Checkpoint Blockade Therapy
Clinical Trials (57)
Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer ( EV-309 )
Hypofractionated Radiotherapy for Postoperative Intermediate-Risk Head and Neck Squamous Cell Carcinoma
Hypofractionated Radiation Therapy vs Standard Treatment in Breast Cancer.
Faecal Incontinence in Prostate Cancer Survivors Treated Whith Radiotherapy
BreastVAX: Radiation Boost to Enhance Immune Checkpoint Blockade Therapy
Iparomlimab and Tuvonralimab Plus Hypofractionated Radiotherapy and Chemotherapy for HAHNSCC
Cetuximab β Combined With PRaG Regimen in the Treatment of EGFR-positive Advanced Refractory Solid Tumors
Hypofractionated Radiotherapy Plus Immunochemotherapy for Neoadjuvant Treatment of Gastroesophageal Junction Adenocarcinoma
Hypofractionated Radiotherapy Combined With Immunochemotherapy for Conversion Treatment of Gastroesophageal Junction Adenocarcinoma
Hypofractionated vs Conventional RT After Prosthetic Breast Reconstruction
Radiation Therapy Followed by Tislelizumab and Anlotinib Aeoadjuvant/Adjuvant Therapy for Stage II-IIIA NSCLC
Hypofractionated Radiotherapy +Chemotherapy+ Camrelizumab as Neoadjuvant Therapy for Pancreatic Cancer
Conventional Versus Hypofractionated Radiotherapy With Temozolomide in Elderly Glioblastoma
Radiotherapy With Hyperthermia in Recurrent and Radiation-Induced Sarcomas
A Study of Erlotinib Plus Radiotherapy (RT) for Patients With Advanced or Inoperable Non-Small-Cell Lung Cancer
Hypofractionated Radiotherapy Plus Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Rectal Cancer
A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors
Hypofractionated Radiotherapy for Nasopharyngeal Carcinoma
Hypofractionated Radiotherapy for Soft Tissue Sarcomas
A Study Involving Neoadjuvant Chemoradiotherapy with Hypofractionated Radiotherapy in Patients with Esophageal and Gastroesophageal Junction Adenocarcinoma
Drug Details
- Intervention Type
- RADIATION
- Total Trials
- 57